| HYPofractionated Adjuvant RadioTherapy in 1 versus 2 weeks in high-risk patients with breast cancer (HYPART): a non-inferiority, open-label, phase III randomised trial.Trials | PMID 38167339PMC10763219 | 2024-Jan-02 | 0.80 | The record is a protocol for a non-drug (radiotherapy) trial, not a formal result report of a drug-containing intervention with a time-to-event efficacy endpoint. | 待处理 |
| Salivary Electrostimulation in the Treatment of Radiation Therapy-Induced Xerostomia (LEONIDAS-2): A Multicenter, Randomized, Double-Masked, Sham-Controlled, Phase 3 Trial.Int J Radiat Oncol Biol Phys | PMID 36933846无 PMCID | 2024-Jan-01 | 0.93 | 干预为非药物单独策略,未满足药物干预要求。 | 待处理 |
| Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Prostate Cancer: The Safety Analysis of the Prostate Cancer Study-5, a Groupe de Radio-Oncologie Génito-Urinaire de Quebec Led Phase 3 Trial.Int J Radiat Oncol Biol Phys | PMID 37224928无 PMCID | 2024-Jan-01 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Prophylactic Radiation Therapy Versus Standard of Care for Patients With High-Risk Asymptomatic Bone Metastases: A Multicenter, Randomized Phase II Clinical Trial.J Clin Oncol | PMID 37748124PMC10730067 | 2024-Jan-01 | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.JAMA Cardiol | PMID 37966817PMC10652219 | 2024-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and immunogenicity of locally produced trivalent inactivated influenza vaccine (Tri Fluvac) in healthy Thai adults aged 18-64 years in Nakhon Phanom: A Phase III double blinded, three-arm, randomized, controlled trial.Vaccine | PMID 38042698PMC10733862 | 2024-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| DELIVER: A Safety Study of a Dapivirine Vaginal Ring and Oral PrEP for the Prevention of HIV During Pregnancy.J Acquir Immune Defic Syndr | PMID 38055292PMC11443417 | 2024-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.Allergy Asthma Proc | PMID 38151733无 PMCID | 2024-Jan-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Acceptability, feasibility and preliminary efficacy of low-moderate intensity Constraint Induced Aphasia Therapy and Multi-Modality Aphasia Therapy in chronic aphasia after stroke.Top Stroke Rehabil | PMID 37036031无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study.Clin Gastroenterol Hepatol | PMID 37061109无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sustained efficacy of mepolizumab in patients with severe chronic rhinosinusitis with nasal polyps: SYNAPSE 24-week treatment-free follow-up.Int Forum Allergy Rhinol | PMID 37345861无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| ALPINE2: Efficacy and safety of 14-day vs 28-day inhaled aztreonam for Pa eradication in children with cystic fibrosis.J Cyst Fibros | PMID 37455237无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Seasonal vaccination with RTS,S/AS01E vaccine with or without seasonal malaria chemoprevention in children up to the age of 5 years in Burkina Faso and Mali: a double-blind, randomised, controlled, phase 3 trial.Lancet Infect Dis | PMID 37625434无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial.Paediatr Drugs | PMID 37713021无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patterns of PET-positive residual tissue at interim restaging and risk of treatment failure in advanced-stage Hodgkin's lymphoma: an analysis of the randomized phase III HD18 trial by the German Hodgkin Study Group.Eur J Nucl Med Mol Imaging | PMID 37735258PMC10774157 | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.BioDrugs | PMID 37737952无 PMCID | 2024-Jan | 0.95 | The record describes a Phase III randomized trial of a drug (ixekizumab) for active radiographic axial spondyloarthritis, which is an autoimmune/inflammatory condition, not an oncology (human malignant neoplasm) indication. The primary efficacy endpoint is a proportion (ASAS40 response), not a time-to-event endpoint like OS, PFS, DFS, EFS, RFS, or TTP, and no Kaplan-Meier or HR analysis for such an endpoint is reported. Therefore, it does not meet the core eligibility criteria for the oncology KM digitization cohort. | 待处理 |
| Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.Clin Pharmacol Ther | PMID 37777832无 PMCID | 2024-Jan | 0.80 | The record is from a randomized phase II trial with a drug intervention (xevinapant) and presents original results. However, it does not meet the required criteria: it is a phase II study, not a phase III or phase IIIb trial, and its primary efficacy endpoint is locoregional control (not a standard time-to-event endpoint like OS, PFS, DFS, etc.) with no mention of Kaplan-Meier analysis or hazard ratios. Therefore, it is ineligible. | 待处理 |
| Glycaemic control, body weight, and safety of tirzepatide versus dulaglutide by baseline glycated haemoglobin level in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study.Diabetes Obes Metab | PMID 37794628无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.Ann Hematol | PMID 37804344PMC10761522 | 2024-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Participant Safety in Multisite, Randomized, Double-Blind, Placebo-Controlled Clinical Trials in Hospice/Palliative Care: Data from the Contracted Studies of the Australian National Palliative Care Clinical Studies Collaborative.J Palliat Med | PMID 37824800无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.Ann Oncol | PMID 37866811无 PMCID | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effectiveness of Liposomal Bupivacaine With Bupivacaine Hydrochloride vs Bupivacaine Hydrochloride Alone as a Local Anesthetic for Children Undergoing Ambulatory Urologic Surgery: The Baby ORIOLES Randomized Clinical Trial.J Urol | PMID 37871332无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.Ann Oncol | PMID 37871702无 PMCID | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Ultra-rapid lispro improved postprandial glucose control compared to insulin lispro in predominantly Chinese patients with type 1 diabetes: A prospective, randomized, double-blind phase 3 study.Diabetes Obes Metab | PMID 37871985无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial.Br J Cancer | PMID 37903909PMC10781743 | 2024-Jan | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101).Ann Surg Oncol | PMID 37903951PMC10695869 | 2024-Jan | 0.80 | The record describes a preplanned observational cohort study assessing the impact of imaging-guided localization on surgical performance within a larger phase-III trial. While the parent trial is phase-III, randomized, oncologic, human, and drug-containing, this specific report does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The analysis focuses on surgical/procedural outcomes (lymph node counts, residual disease), which are not time-to-event endpoints. Therefore, it is not eligible for the oncology KM digitization cohort. | 待处理 |
| Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial.Ann Oncol | PMID 37922989无 PMCID | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Fostamatinib for warm antibody autoimmune hemolytic anemia: Phase 3, randomized, double-blind, placebo-controlled, global study (FORWARD).Am J Hematol | PMID 37929318无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Clinical Bridging From Prefilled Syringe to On-body Injector for Risankizumab in Crohn's Disease.Clin Ther | PMID 37932155无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.Diabetes Obes Metab | PMID 37932236无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.Leukemia | PMID 37935977PMC11729399 | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.Lancet Haematol | PMID 37980924无 PMCID | 2024-Jan | 0.85 | While the trial meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result, the primary efficacy endpoint is a non-inferiority/superiority comparison of venous thromboembolism incidence (reported as relative risk), not a time-to-event oncology endpoint like OS or PFS. Therefore, it does not meet the time-to-event criterion required for inclusion in this cohort. | 待处理 |
| Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis and comorbid allergies.Allergy | PMID 37988255无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients and implications for clinical practice.Oral Oncol | PMID 37988838无 PMCID | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer.Gastric Cancer | PMID 37989806无 PMCID | 2024-Jan | 0.95 | All required criteria are explicitly met: it is an original, formal-result report of a Phase III randomized trial in human oncology (gastric cancer) evaluating a drug intervention (S-1) with primary/key secondary time-to-event efficacy endpoints (RFS and OS, reported with Kaplan-Meier estimates and HRs). | 待处理 |
| Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.BioDrugs | PMID 37991693PMC10789833 | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase III clinical trial comparing the efficacy and safety of adamgammadex with sugammadex for reversal of rocuronium-induced neuromuscular block.Br J Anaesth | PMID 38007377无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improvements in pincer nail deformity occur earlier and last longer when acetylcysteine gel is added to an overcurvature-correcting device: Results of a phase 3, multicenter, randomized, vehicle-controlled, investigator-blinded study.J Dermatol | PMID 38009825PMC11483967 | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Thrombolysis with Recombinant Human Prourokinase 4.5-6 h After Acute Ischemic Stroke: A Phase IIa, Randomized, and Open-Label Multicenter Clinical Trial.CNS Drugs | PMID 38030867PMC10811005 | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Lunchbox trial: A randomized phase III trial of cisplatin and irradiation followed by carboplatin and paclitaxel versus sandwich therapy of carboplatin and paclitaxel followed by irradiation then carboplatin and paclitaxel for advanced endometrial carcinoma.Gynecol Oncol | PMID 38052110无 PMCID | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.Lancet Diabetes Endocrinol | PMID 38061371PMC7615591 | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.Lancet Diabetes Endocrinol | PMID 38061372PMC7618536 | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase 3 efficacy and safety trial of proposed liraglutide biosimilar for reduction of glycosylated hemoglobin (HbA1c) in patients with Type 2 diabetes mellitus.Diabetes Res Clin Pract | PMID 38061446无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Haematol | PMID 38065203无 PMCID | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.Lancet Oncol | PMID 38101431无 PMCID | 2024-Jan | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study.Lancet Oncol | PMID 38101433无 PMCID | 2024-Jan | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study.ESMO Open | PMID 38118368PMC10837773 | 2024-Jan | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study.Lancet Haematol | PMID 38135371无 PMCID | 2024-Jan | 0.95 | While the study is an oncology Phase 3 randomized trial with a drug intervention and reports original results, it does not meet the cohort's inclusion criteria because the primary endpoint is pharmacokinetic equivalence (AUC), not a time-to-event efficacy endpoint such as overall survival, progression-free survival, or disease-free survival. No Kaplan-Meier curves or hazard ratios for such endpoints are described in the provided abstract. | 待处理 |
| Efficacy and safety of intravenous belimumab in a subgroup of South Korean patients with systemic lupus erythematosus enrolled into a Phase 3, randomized, placebo-controlled trial in North East Asia.Int J Rheum Dis | PMID 38140854无 PMCID | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL).Intensive Care Med | PMID 38172296PMC10810941 | 2024-Jan | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |